ImmunoGen Inc, earns a $5 Million payment for the start of the study and research of a Phase 1 study of PCA062, a cancer therapy candidate based on ImmunoGen’s antibody-drug conjugate technology.
View the full release here.
ImmunoGen Inc, earns a $5 Million payment for the start of the study and research of a Phase 1 study of PCA062, a cancer therapy candidate based on ImmunoGen’s antibody-drug conjugate technology.
View the full release here.